Anti-NMNAT1 / Nicotinamide mononucleotide adenylyltransferase 1

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. NMNAT1 antibody targets Nicotinamide mononucleotide adenylyltransferase 1, a key nuclear enzyme in the NAD+ biosynthetic pathway. NMNAT1 catalyzes the conversion of nicotinamide mononucleotide (NMN) and ATP to NAD+ and pyrophosphate, representing the final step in the salvage pathway that maintains cellular NAD+ levels. This metabolite is vital for redox reactions, DNA repair, and signaling processes involving sirtuins and PARPs. The NMNAT family includes three isoforms-NMNAT1 (nuclear), NMNAT2 (cytoplasmic/golgi), and NMNAT3 (mitochondrial)-each serving tissue-specific and compartment-specific functions. Among them, NMNAT1 localizes to the nucleus and associates with DNA repair machinery, chromatin remodelers, and transcriptional regulators.Genetic studies have established that NMNAT1 is essential for embryonic viability and neuronal survival. Mutations in the NMNAT1 gene cause Leber congenital amaurosis type 9 (LCA9), a severe inherited retinal dystrophy characterized by early-onset vision loss due to impaired photoreceptor maintenance. The enzyme's role in maintaining nuclear NAD+ pools underlies its protective effects against oxidative and genotoxic stress. Beyond ocular disease, NMNAT1 contributes to genomic stability by supporting PARP-dependent DNA damage responses. Cellular NAD+ depletion impairs repair efficiency, highlighting NMNAT1 as a therapeutic target for age-related degeneration and metabolic disorders.In neurobiology, NMNAT1 has gained attention for its neuroprotective potential. Experimental models demonstrate that increasing NMNAT1 expression can delay axonal degeneration following injury, a phenomenon known as Wallerian degeneration slow (WldS). This protective capacity likely arises from preserved nuclear NAD+ synthesis, influencing downstream survival pathways. Moreover, NMNAT1 coordinates with sirtuin-1 (SIRT1) to regulate gene expression and chromatin structure through histone deacetylation mechanisms. Disruption of this balance is linked to premature cellular aging and retinal degeneration.The NMNAT1 antibody is a critical reagent for probing NAD+ metabolism, DNA repair, and neuroprotection pathways. Researchers use it for western blotting, immunocytochemistry, and immunohistochemistry to detect endogenous NMNAT1 across cell types. Its nuclear localization pattern provides a distinct marker for studying NAD+ biosynthesis compartmentalization. In clinical research, NMNAT1 expression is analyzed in retinal tissues, cancer cell lines, and aging models to evaluate metabolic resilience. The antibody's specificity allows discrimination between NMNAT1 and its cytoplasmic and mitochondrial isoforms, ensuring accurate interpretation of NAD+-related experiments.Because of its central role in redox regulation, NMNAT1 represents a molecular intersection between energy metabolism, genome integrity, and cellular stress responses. By targeting this enzyme, the NMNAT1 antibody supports studies into retinal dystrophy, neurodegeneration, and therapeutic NAD+ augmentation strategies. NSJ Bioreagents provides a validated NMNAT1 antibody optimized for western blot and immunohistochemical assays, enabling precise analysis of nuclear NAD+ metabolism and DNA repair pathways.